Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases

Newsylist Editorial Desk. (2026, June 29, 2026). Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-06-29/talawar-therapeutics-and-jatt-ii-acquisition-corp-announce-definitive-business

@online{newsylist_3941,
  author = {Newsylist Editorial Desk},
  title = {{Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-06-29/talawar-therapeutics-and-jatt-ii-acquisition-corp-announce-definitive-business},
  note = {Tracked across 5 independent newsrooms}
}

> According to Newsylist Editorial Desk ([Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases](https://www.newsylist.com/trend/2026-06-29/talawar-therapeutics-and-jatt-ii-acquisition-corp-announce-definitive-business)), this event was corroborated across 5 independent sources with a live velocity of 3.